NCT05380453 - Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission | Biotech Hunter

Enrollment

151

Participants

Timeline

Start Date

September 21, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions

Giant Cell Arteritis

Interventions

BIOLOGICAL

Secukinumab 300 mg, s.c.

Secukinumab will be administered at a dose of 300 mg as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.

DRUG

Placebo to match Secukinumab, s.c.

Placebo will be administered as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.

Trial Locations (27)

12161

Novartis Investigative Site, Berlin

12435

Novartis Investigative Site, Berlin

13125

Novartis Investigative Site, Berlin

13353

Novartis Investigative Site, Berlin

24768

Novartis Investigative Site, Rendsburg

30625

Novartis Investigative Site, Hanover

32429

Novartis Investigative Site, Minden

37075

Novartis Investigative Site, Göttingen

39245

Novartis Investigative Site, Gommern

40225

Novartis Investigative Site, Düsseldorf

44649

Novartis Investigative Site, Herne

48324

Novartis Investigative Site, Sendenhorst

50937

Novartis Investigative Site, Cologne

51149

Novartis Investigative Site, Cologne

54292

Novartis Investigative Site, Trier

55131

Novartis Investigative Site, Mainz

61231

Novartis Investigative Site, Bad Nauheim

67063

Novartis Investigative Site, Ludwigshafen

69120

Novartis Investigative Site, Heidelberg

79106

Novartis Investigative Site, Freiburg im Breisgau

81667

Novartis Investigative Site, München

91054

Novartis Investigative Site, Erlangen

93077

Novartis Investigative Site, Bad Abbach

97080

Novartis Investigative Site, Würzburg

01067

Novartis Investigative Site, Dresden

01307

Novartis Investigative Site, Dresden

07740

Novartis Investigative Site, Jena